tbuckley/cabot-search huggingface dataset:
Clinical features of isolated noncompaction of the ventricular myocardium
Authors: Fukiko Ichida, Yuji Hamamichi, Toshio Miyawaki, Yasuo Ono, Tetsuro Kamiya, Teiji Akagi, Hiromichi Hamada, Osamu Hirose, Takeshi Isobe, Katsuhiko Yamada, Shunji Kurotobi, Hiroshi Mito, Toshiharu Miyake, Yasuo Murakami, Takeshi Nishi, Makoto Shinohara, Masashi Seguchi, Shinjiro Tashiro, Hirofumi Tomimatsu
Journal: Journal of the American College of Cardiology (1999)
Radiation therapy and survival in breast cancer patients with 10 or more positive axillary lymph nodes treated with mastectomy.
Authors: S G Diab, S G Hilsenbeck, C de Moor, G M Clark, C K Osborne, P M Ravdin, R M Elledge
Journal: Journal of Clinical Oncology (1998)

PURPOSE Adjuvant loco-regional radiation (XRT) frequently is recommended after mastectomy and adjuvant systemic therapy in patients with 10 or more positive axillary lymph nodes (ALN) to reduce the high loco-regional failure rate observed in this subset. In this study, we explored the possibility that adjuvant loco-regional radiation therapy (LR-XRT) also could decrease distant failure and improve overall survival (OS) in this subset of poor-prognosis patients. PATIENTS AND METHODS Retrospectively, 618 breast patients with 10 or more positive ALN were studied. The median follow-up time was 7.5 years. All patients received systemic adjuvant therapy and 35% also received adjuvant radiation therapy. Loco-regional failure, distant failure, and OS analyses were adjusted for age, tumor size, number of positive ALN, and estrogen receptor (ER) status using Cox regression model. RESULTS As expected, patients had a very high risk of loco-regional and distant failure. At 5 years, 30% of patients had loco-regional failure as a first event and 54% had distant failure. Radiation dramatically reduced loco-regional failure (hazards rate ratios [RR]=0.29; 95% confidence interval [CI], 0.19 to 0.45). The adjusted 5-year loco-regional failure rate was 13% with radiation and 38% without radiation (P=.0001). Radiation also was associated with improved distant control (RR=0.75; 95% CI, 0.58 to 0.96). The adjusted 5-year distant failure rate was 48% with radiation and 58% without radiation (P=.02). OS also improved with radiation (RR=0.68; 95% CI, 0.53 to 0.85). The adjusted 5-year OS was 56% with radiation and 42% without radiation (P=.001). CONCLUSION In this cohort of high-risk breast cancer patients, XRT was associated with less loco-regional and distant failure and improved OS. This suggests that improved loco-regional control might decrease secondary systemic spread and improve survival.
Non-CF bronchiectasis: Correlation between body mass composition, lung function, inflammatory syndrome, gender and quality of life
Authors: Adina Turcanu, Traian Mihaescu
Journal: European Respiratory Journal (2012)

Background:  The impact of bronchiectasis on health care9s costs and quality of life is important due to prolonged and repeated periods of hospitalization.   Aim:  Asses the situation of hospitalized persons diagnosed with non-CF bronchiectasis by studying the relationship between body mass composition,pulmonary function and gender;to study how these parameters correlate with the inflammatory profile associated with acute recurrent respiratory infections.   Methods:  30 consecutive patients(15 male,15 women) enrolled in 2011,evaluated through HRCT,bioimpedance,spirometry,inflammatory profile and Saint George Questionnaire.   Results:  We observed that 70% of the patients(12 male and 9 women) had high percent of fat,the percentage of water was low at 50% of the patients(9 male;6 women);also,the lean percentage was low at 28 patients(equal for both sex).  Regarding the pulmonary function and the inflammatory syndrome we observed that 90%(27 patients) had abnormal values for CRP and ESR, and all patients had obstructive dysfunction syndrome(FEV1 between 34-85 % from predicted values).  80% of the answers from Saint George Questionnaire indicated that the quality of life was medium to poor.We correlate this to low percent of lean and water,the presence of inflammatory syndrome and obstructive respiratory syndrome.   Conclusions:  Body mass composition in patients with non-CF bronchiectasis is modified,more in male than in women,probably due to chronic lung disease and recurrent infections associated with the inflammatory syndrome.Obstructive lung syndrome is present at almost all the patients and with the rest of parameters can be correlated with the decrease of the quality of life.
Radioimmunodetection and radioimmunotherapy of cutaneous T cell lymphomas using an 131I-labeled monoclonal antibody: an Illinois Cancer Council Study.
Authors: S T Rosen, A M Zimmer, R Goldman-Leikin, L I Gordon, J M Kazikiewicz, E H Kaplan, D Variakojis, R J Marder, M S Dykewicz, A Piergies
Journal: Journal of Clinical Oncology (1987)

A radiolabeled murine monoclonal antibody (T101) was used for imaging and therapy of six patients with cutaneous T cell lymphoma (CTCL). Radioimmunodetection was performed with a 5.6 to 13.1 mCi 131I-T101 preparation (9.6 to 10.5 mg). A therapeutic dose of 100.5 to 150.1 mCi 131I on 9.9 to 16.9 mg of antibody was administered to five patients, with subsequent retreatment following plasmapheresis in three patients at the time of disease progression. All patients responded to their initial therapy and two patients responded to retreatment. Regression of skin lesions and peripheral adenopathy was witnessed. All patients reported resolution of their chronic pruritus. The duration of response ranged from 3 weeks to 3 months. Acute toxicity included fevers, pruritus, and mild dyspnea in two instances. Myelosuppression was seen in patients receiving the 144.7 mCi, 145.0 mCi, and 150.1 mCi 131I-T101 doses. Radioimmunodiagnostic and therapy studies included gamma scintigraphy, plasma, urinary, and wholebody antibody clearances, and biodistribution determined from skin, bone marrow, and liver biopsies. Immunologic studies included immunoperoxidase staining of target tissues, immunofluorescent flow cytometric analysis on peripheral blood and bone marrow, assays for serum blocking factors, determination of a human antimouse antibody (HAMA) response, and quantitation of circulating T101 levels. These preliminary data suggest that 131I-T101 has therapeutic potential in CTCL and that myelosuppression will be the limiting toxicity.
Clinical outcomes of bilateral lung transplantation for cystic fibrosis in frame of the european multicentric COLT study
Authors: Adrien Tissot, Phillipe Lacoste, Pierre Joseph Royer, A. Roux, M. Raynault-Gaubert, L. Kessler, Karine Botturi, Mallory Pain, Antoine Magnan
Journal: European Respiratory Journal (2014)

The main long term complication of lung transplantation is CLAD (Chronic Lung Allograft Dysfunction). COLT (Cohort in Lung Transplantation) is the largest biocollection in Europe set up in order to identify a biological marker of CLAD.  The objective of the study is to describe clinical outcomes of cystic fibrosis (CF) patients in COLT, with at least one year follow up post transplantation.  From september 2009 to june 2012, 156 CF patients underwent bilateral lung transplantation. 48% were men, with mean age 27,5 and 18 IMC. 65% lung transplant recipients (LTR) with CF were infected with  Pseudomonas aeruginosa , 33% with  Staphylococcus Aureus . Before transplantation, 38% patients were colonizated with  Aspergillus Fumigatus . The median time on waiting list was 123+/- 418 days with 27% High Emergency (HE) transplanted patients (waiting time: 7 +/- 5 days). 38% were transplanted with a miss-match of CMV, 12% for EBV. Patients required invasive ventilation during 9 days (median: 2 days) in intensive care unit. The post-transplantation morbidity was: 12,8% tracheotomy, 12% dialysis, 12% Extra Corporeal Membrane Oxygenation support. The actuarial survival rates were respectively 89%, 85,4%, and 85,4% at 1, 2 and 3 years. Concerning HE transplanted patients, the actuarial survival rates were respectively 80,5 %, 75,5%, and 75,5% at 1, 2 and 3 years. Evolution of mean FEV1 was 76, 81, and 69 % at 1, 2 and 3 years.  This work shows encouraging results in COLT of bilateral lung transplantation in term of morbi-mortality, even for HE transplanted patients. The COLT study represents a large population which should allowed great improvement in CLAD understanding.
Endophytes as a potential source of new anticancer agents
Authors: Kalavathy R, Lim Sm, Abu Bakar H, Ismail N, Ariffin N F, Ismail M S, Weber J F F
Journal: Clinical Cancer Research (2007)

AACR Centennial Conference: Translational Cancer Medicine-- Nov 4-8, 2007; Singapore

C31 

A recent decline in obtaining natural products has created a need for alternative sources. Endophytes, which are still poorly explored, have been found to be an outstanding source of bioactive metabolites following the discovery of paclitaxel producing fungus. Of the 350 endophytic extracts screened against P388, a murine leukemic cell line, 61% were categorized as non-active and 39% were otherwise (IC50<20μg/ml). In fact, three of the endophytic extracts had an IC50 of < 0.1 μg/ml. These extracts were further tested against tumor type (HCT116 and MCF7) and non-tumor type (Chang) cell lines. Generally, the endophytic extracts were found to be five times more potent than oxaliplatin and about 15 times to that of the 5-FU. On the contrary, only one out of three active endophytic extracts was found to be more potent than paclitaxel but not that of tamoxifen. When compared the cell line selectivity of the three endophytic extracts, they were generally more selective towards tumor type cell lines. The extracts were 210 times more selective towards HCT116 and 26 times more selective towards MCF7, with Chang as the reference for comparison. The selectivity of the endophytic extracts towards tumour type cell lines may contribute to the effective use of these extracts as effective anticancer agents. Further subjection of these extracts to bioactivity guided fractionation and dereplication techniques found two out of three extracts to possess unknown compounds. More extensive investigations should be carried out to uncover the anticancer potential of these extracts.
Cell surface characterization of malignant T cells from lymphoblastic lymphoma using monoclonal antibodies: evidence for phenotypic differences between malignant T cells from patients with acute lymphoblastic leukemia and lymphoblastic lymphoma
Authors: A Bernard, L Boumsell, EL Reinherz, LM Nadler, J Ritz, H Coppin, Y Richard, F Valensi, J Dausset, G Flandrin, J Lemerle, SF Schlossman
Journal: Blood (1981)
Molecular Marker Analyses of Egfr and Kras from the Randomized Phase Ii Study of Nimotuzumab in Locally Advanced Esophageal Cancer (Nice Trial)
Authors: G. De Castro, N. Skare, J.G.M. Segalla, S. Azevedo, C.J. Andrade, D. Grabarz, B. Franca, A. Del Giglio, N. Lazaretti, M.N. Álvares, J.L. Pedrini, C. Kussumoto, J.N.D. Matos Neto, N. Forones, H. Fernandes, G. Borges, G.C. Girotto, L.P.D.G. Neusquen, I. Dale
Journal: Annals of Oncology (2014)
Targeting Mitochondria with Avocatin B Induces Selective Leukemia Cell Death
Authors: Eric A. Lee, Leonard Angka, Sarah-Grace Rota, Thomas Hanlon, Andrew Mitchell, Rose Hurren, Xiao Ming Wang, Marcela Gronda, Ezel Boyaci, Barbara Bojko, Mark Minden, Shrivani Sriskanthadevan, Alessandro Datti, Jeffery L. Wrana, Andrea Edginton, Janusz Pawliszyn, Jamie W. Joseph, Joe Quadrilatero, Aaron D. Schimmer, Paul A. Spagnuolo
Journal: Cancer Research (2015)

Treatment regimens for acute myeloid leukemia (AML) continue to offer weak clinical outcomes. Through a high-throughput cell-based screen, we identified avocatin B, a lipid derived from avocado fruit, as a novel compound with cytotoxic activity in AML. Avocatin B reduced human primary AML cell viability without effect on normal peripheral blood stem cells. Functional stem cell assays demonstrated selectivity toward AML progenitor and stem cells without effects on normal hematopoietic stem cells. Mechanistic investigations indicated that cytotoxicity relied on mitochondrial localization, as cells lacking functional mitochondria or CPT1, the enzyme that facilitates mitochondria lipid transport, were insensitive to avocatin B. Furthermore, avocatin B inhibited fatty acid oxidation and decreased NADPH levels, resulting in ROS-dependent leukemia cell death characterized by the release of mitochondrial proteins, apoptosis-inducing factor, and cytochrome c. This study reveals a novel strategy for selective leukemia cell eradication based on a specific difference in mitochondrial function.
Cancer Induction in the Glandular Stomach of Rats at Sites of Implanted 7,12-Dimethylbenz[a]anthracene2
Authors: Rhoda Grant
Journal: JNCI Journal of the National Cancer Institute (1966)

When 2–3 mg of 7,12-dimethylbenz[a]anthracene (DMBA) was implanted surgically without carrier material, such as thread, wax, or Gelfoam in the submucosa of the glandular stomach of 22 rats, cancer developed at the implant site in 13 (59%) in from 5 to 16 months. Apart from 1 mucinous adenocarcinoma and 1 squamous cell carcinoma, the malignant neoplasms were of 2 cell types. Type 1 was formed of large epithelium-like cells of uncertain origin. Type 2 consisted of fusiform cells probably originating in smooth muscle cells or fibroblasfs. There was metastasis to the liver in one rat, and direct invasion of the liver in a second and of the liver, spleen, and pancreas in a third. The incidence of malignant gastric neoplasms induced under these experimental conditions was markedly increased over the incidence previously found in the rat after the surgical implantation or the injection of the same or smaller quantities of 3-methyl-cholanthrene with or without other material, and also exceeded the incidence after the surgical implantation of 2.5 mg or smaller quantities of DMBA with carrier material. Most neoplasms, however, were of mixed epithelial or epithelium-like and mesenchymal origins. In this respect they corresponded with the neoplasms previously induced by the injection or surgical implantation of carcinogenic hydrocarbons in the stomach wall of rodents.
Abstract 2889: Pyruvate-enriched Cardioplegia Evokes Novel Erythropoietin Expression and Signaling in Porcine Myocardium
Authors: Myoung-Gwi Ryou, Devin C Flaherty, Besim Hoxha, Jie Sun, Albert H Olivencia-Yurvati, Robert T Mallet
Journal: Circulation (2008)
Ankyrin-B metabolic syndrome combines age-dependent adiposity with pancreatic β cell insufficiency
Authors: Damaris N. Lorenzo, Jane A. Healy, Janell Hostettler, Jonathan Davis, Jiayu Yang, Chao Wang, Hans Ewald Hohmeier, Mingjie Zhang, Vann Bennett
Journal: Journal of Clinical Investigation (2015)

Rare functional variants of ankyrin-B have been implicated in human disease, including hereditary cardiac arrhythmia and type 2 diabetes (T2D). Here, we developed murine models to evaluate the metabolic consequences of these alterations in vivo. Specifically, we generated knockin mice that express either the human ankyrin-B variant R1788W, which is present in 0.3% of North Americans of mixed European descent and is associated with T2D, or L1622I, which is present in 7.5% of African Americans. Young AnkbR1788W/R1788W mice displayed primary pancreatic β cell insufficiency that was characterized by reduced insulin secretion in response to muscarinic agonists, combined with increased peripheral glucose uptake and concomitantly increased plasma membrane localization of glucose transporter 4 (GLUT4) in skeletal muscle and adipocytes. In contrast, older AnkbR1788W/R1788W and AnkbL1622I/L1622I mice developed increased adiposity, a phenotype that was reproduced in cultured adipocytes, and insulin resistance. GLUT4 trafficking was altered in animals expressing mutant forms of ankyrin-B, and we propose that increased cell surface expression of GLUT4 in skeletal muscle and fatty tissue of AnkbR1788W/R1788W mice leads to the observed age-dependent adiposity. Together, our data suggest that ankyrin-B deficiency results in a metabolic syndrome that combines primary pancreatic β cell insufficiency with peripheral insulin resistance and is directly relevant to the nearly one million North Americans bearing the R1788W ankyrin-B variant.
Abstract 14962: Myocardial Blood Flow changes during Cold Pressor Testing for the assessment of endothelial function. A Cardiovascular Magnetic Resonance study.
Authors: Timothy A Fairbairn, Manish Motwani, Adam N Mather, John D Biglands, Abdulghani M Larghat, John P Greenwood, Sven Plein
Journal: Circulation (2011)

Introduction: Cold Pressor Testing (CPT) is an endothelial dependent stressor that can assess the functional integrity of the endothelium and diagnose early coronary endothelial dysfunction, for ex...
Clinical relevance of aspergillus positive endotracheal aspirate cultures in critically ill patients : validation of an algorithm to discriminate aspergillus colonization from invasive pulmonary aspergillosis
Authors: Stijn Blot, Nele Brusselaers, FS Taccone, P Bulpa, AM Van den Abeele, G Dimopoulos, JA Paiva, B Misset, J Rello, Koenraad Vandewoude, Dirk Vogelaers
Journal: Intensive Care Medicine (2010)
The Aryl Hydrocarbon Receptor is a Critical Regulator of Tissue Factor Stability and an Antithrombotic Target in Uremia
Authors: Sowmya Shivanna, Kumaran Kolandaivelu, Moshe Shashar, Mostafa Belghasim, Laith Al-Rabadi, Mercedes Balcells, Anqi Zhang, Janice Weinberg, Jean Francis, Michael P. Pollastri, Elazer R. Edelman, David H. Sherr, Vipul C. Chitalia
Journal: Journal of the American Society of Nephrology (2015)

Patients with CKD suffer high rates of thrombosis, particularly after endovascular interventions, yet few options are available to improve management and reduce thrombotic risk. We recently demonstrated that indoxyl sulfate (IS) is a potent CKD-specific prothrombotic metabolite that induces tissue factor (TF) in vascular smooth muscle cells (vSMCs), although the precise mechanism and treatment implications remain unclear. Because IS is an agonist of the aryl hydrocarbon receptor (AHR), we first examined the relationship between IS levels and AHR-inducing activity in sera of patients with ESRD. IS levels correlated significantly with both vSMC AHR activity and TF activity. Mechanistically, we demonstrated that IS activates the AHR pathway in primary human aortic vSMCs, and further, that AHR interacts directly with and stabilizes functional TF. Antagonists directly targeting AHR enhanced TF ubiquitination and degradation and suppressed thrombosis in a postinterventional model of CKD and endovascular injury. Furthermore, AHR antagonists inhibited TF in a manner dependent on circulating IS levels. In conclusion, we demonstrated that IS regulates TF stability through AHR signaling and uncovered AHR as an antithrombotic target and AHR antagonists as a novel class of antithrombotics. Together, IS and AHR have potential as uremia-specific biomarkers and targets that may be leveraged as a promising theranostic platform to better manage the elevated thrombosis rates in patients with CKD.
Simulator training for endobronchial ultrasound: a randomised controlled trial
Authors: Lars Konge, Paul Frost Clementsen, Charlotte Ringsted, Valentina Minddal, Klaus Richter Larsen, Jouke T. Annema
Journal: European Respiratory Journal (2015)

Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) is very operator dependent and has a long learning curve. Simulation-based training might shorten the learning curve, and an assessment tool with solid validity evidence could ensure basic competency before unsupervised performance. A total of 16 respiratory physicians, without EBUS experience, were randomised to either virtual-reality simulator training or traditional apprenticeship training on patients, and then each physician performed EBUS-TBNA procedures on three patients. Three blinded, independent assessor assessed the video recordings of the procedures using a newly developed EBUS assessment tool (EBUSAT). The internal consistency was high (Cronbach's α=0.95); the generalisability coefficient was good (0.86), and the tool had discriminatory ability (p&lt;0.001). Procedures performed by simulator-trained novices were rated higher than procedures performed by apprenticeship-trained novices: mean± sd are 24.2±7.9 points and 20.2±9.4 points, respectively; p=0.006. A pass/fail standard of 28.9 points was established using the contrasting groups method, resulting in 16 (67%) and 20 (83%) procedures performed by simulator-trained novices and apprenticeship-trained novices failing the test, respectively; p&lt;0.001. The endobronchial ultrasound assessment tool could be used to provide reliable and valid assessment of competence in EBUS-TBNA, and act as an aid in certification. Virtual-reality simulator training was shown to be more effective than traditional apprenticeship training.
Long-term survival in small-cell lung cancer: posttreatment characteristics in patients surviving 5 to 18+ years--an analysis of 1,714 consecutive patients.
Authors: U Lassen, K Osterlind, M Hansen, P Dombernowsky, B Bergman, H H Hansen
Journal: Journal of Clinical Oncology (1995)

PURPOSE To describe in patients with small-cell lung cancer (SCLC) the characteristics of those who survive for &gt; or = 5 years, to identify long-term prognostic factors, to analyze survival data of 5-year survivors, and to study 10-year survival in patients entered before 1981. PATIENTS AND METHODS A total of 1,714 unselected patients with SCLC were treated with combination chemotherapy in nine consecutive clinical trials from 1973 to 1991. All medical records were reviewed and follow-up data obtained to analyze and compare pretreatment and posttreatment characteristics. RESULTS Sixty patients survived longer than 5 years. Late relapses occurred in 15.0% of 5-year survivors and secondary malignancies in 20.0%. Twenty-six patients are still alive and disease-free 5 to 18 years (median, 9.5 years) from initiation of treatment. Extensive-stage disease, performance status (PS) more than 2, liver and bone marrow metastases, and elevated lactate dehydrogenase (LDH) and alkaline phosphatase levels were all negative prognostic factors. The 5-year survival rate was 3.5% (limited-stage disease, 4.8%; extensive-stage disease, 2.3%), and the 10-year survival rate was 1.8% (limited-stage disease, 2.5%; extensive-stage disease, 1.2%). CONCLUSION Long-term survival can be achieved for both stages of SCLC, but without any change in survival rates over the last decade. Long-term survivors continuously seem to have considerable mortality due to late relapses and secondary malignancies, especially tobacco-related cancers and other tobacco-related diseases.